课题基金 / 基金详情

Study for both the establishment of in vivo model system for the development of salivary mucous cyst and its treatment

Study for both the establishment of in vivo model system for the development of salivary mucous cyst and its treatment
唾液腺粘液囊肿体内模型系统的建立及其治疗研究
批准号:
06557112
负责人:
AZUMA Masayuki
金额:
$6.53万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1995

项目摘要

项目成果

AZUMA Masayuki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We have examined the content of matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) in luminal fluid of extravasation mucoceles. The luminal fluid showed a high level of MMP activity compared with saliva from Wharton's duct. This result suggests that proteolytic enzymes are involved in the pathogenesis of mucoceles. Thus, based on the above observation, we attempted to construct a cyst-like structure in vivo, and analyzed molecular mechanisms in the development of the lesion. When SV40-immortalized normal human salivary gland cells (NS-SV-DC) were treated with TGF-beta1 at the concentration of 1 ng/ml or 5 ng/ml followed by co-inoculation with Matrigel into the backs of nude mice, they formed large cystic structures containing luminal fluid. Analysis of luminal fluids contained in cystic cavity demonstrated a high MMP activity. Northern blot analysis indicated that expression of TGF-beta1 and MMP-2 mRNAs in cells was greatly enhanced by treatment with TGF-beta1. Furthermore, the development of cyst formation was almost completely inhibited by the addition of TIMP-1 into Matrigel. These findings, therefore, suggest that the in vivo cyst formation by TGF-beta1-treated cells is associated with the continuous induction of MMP-2 activity.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
東 雅之: "SV40不死化正常ヒト唾液腺細胞における野生型p53の発現" 日本口腔科学会雑誌. 43. 580-585 (1994)
Masayuki Higashi:“野生型 p53 在 SV40 永生化正常人唾液腺细胞中的表达”日本口腔医学会杂志 43. 580-585 (1994)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masayuki Azuma: "Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones." Int.J.Cancer. (in press).
Masayuki Azuma:“转化生长因子-β II 型受体的表达缺乏与人类唾液腺细胞克隆的恶性进展相关。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masayuki Azuma: "Different signal pathways involved in transforming growth factor-β1-induced morphologic change and type IV collagen synthesis in SV40-immortalized normal human salivary gland duct and myoeaithlial cell clone" Arch.Oral Biol.(in press). (1
Masayuki Azuma:“SV40 永生化正常人唾液腺管和肌细胞克隆中转化生长因子-β1 诱导的形态变化和 IV 型胶原蛋白合成中涉及的不同信号通路”Arch.Oral Biol.(出版中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masayuki Azuma: "Expression of wild-type p53 in SV40-immortalized normal human salivary gland cells." J.Jpn.Stomatol.Soc.43. 580-585 (1994)
Masayuki Azuma:“野生型 p53 在 SV40 永生化正常人唾液腺细胞中的表达。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
16
    Development of a novel treatment for Sjogren's syndrome on the basis of the regulation of molecules related to the syndrome
    • 批准号:
      17K11842
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2017
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    Development of the microbial catalyst suitable for a bio-fuel cell by integrating superior functions in Escherichia coli
    • 批准号:
      26420797
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.24万
    • 财政年份:
      2014
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    A novel histopathology of oral lichen plans and its therapeutic strategy
    • 批准号:
      24659896
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2012
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    Study to raise the performance of the glucose fuel cell "Improvement of the electronic acquisition technology from the microbe in the fuel cell"
    • 批准号:
      22560773
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2010
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    海外基金